|
業務類別
|
Biotechnology |
|
業務概覽
|
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics. |
| 公司地址
| 161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 866-8547 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.denalitherapeutics.com |
| 員工數量
| 503 |
| Dr. Ryan J. Watts, PhD |
Director, President and Chief Executive Officer |
美元 690.10K |
26/02/2026 |
| Dr. Alexander O. Schuth, M.D. |
Secretary, Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer |
美元 535.60K |
26/02/2026 |
| Dr. Carole Ho, M.D. |
Chief Medical Officer and Head of Development |
美元 535.60K |
17/04/2025 |
|
|
| Mr. Julian C. Baker |
Independent Director |
26/02/2026 |
| Ms. Nancy A. Thornberry |
Independent Director |
26/02/2026 |
| Ms. Jennifer E. Cook |
Independent Director |
26/02/2026 |
| Dr. David P. Schenkein, M.D. |
Independent Director |
26/02/2026 |
| Dr. Marc Tessier-Lavigne, PhD |
Independent Director |
17/04/2025 |
| Mr. Jay T. Flatley |
Independent Director |
26/02/2026 |
| Dr. Ryan J. Watts, PhD |
Director, President and Chief Executive Officer |
26/02/2026 |
| Mr. Steven E. Krognes, M.B.A. |
Director |
26/02/2026 |
| Mr. Peter S. Klein |
Independent Director |
26/02/2026 |
| Mr. Tim Van Hauwermeiren, M. Sc. |
Director |
26/02/2026 |
|
|
|
|
